Recently, vitamin C alone or in combination with other therapies has been utilized to target NF-κB activity in a variety of in vitro and in vivo cancers, such as skin cutaneous melanoma (SKCM), lung adenocarcinoma (LUAD), esophageal cancer, cervical cancer, CRC, melanoma, and thyroid carcinoma (THCA) [104]. Here, NFKB1 is linked to cancer.